tbuckley/cabot-search huggingface dataset:
S55 Using continuous positive airway pressure (cpap) in excessive dynamic airway collapse (edac)
Authors: AP Hicks, T Brown, A Chauhan, K Adeniji, M Quint, S Babu
Journal: Thorax (2016)

<h3></h3> EDAC is a term that refers to the pathological collapse of respiratory airways during expiration as a result of posterior wall muscle laxity leading to a &gt;50% loss of airway cross-sectional area. This muscle laxity leads to a loss of airway patency which results in symptomatic dyspnoea. CPAP has been suggested as a method to ameliorate the difficulties associated with EDAC where standard medical care has failed, ameliorating the need for further invasive treatments such as endobronchial stenting or tracheoplasty. Demonstrating its effectiveness is difficult as many of those who suffer with EDAC have co-morbid disease such as COPD, asthma or EGPA which may mask the impact of CPAP when measuring response with subjective criteria such as the WHO functional impairment scale. We set out to determine whether we could objectively demonstrate improvements in airway diameter using CPAP in patients with EDAC, in addition to COPD and EGPA, using firstly bronchoscopy and secondly dynamic computed tomography (CT). In both cases we used a Philips Respironics Trilogy 200 CPAP device to deliver positive airway pressure at 5 cm increments up to a pressure of 20 cmH2O. Figure 1a shows a bronchoscopic example of this process with an increase in airway area from 1.54cm<sup>2</sup> to 5.35cm<sup>2</sup> equating to a 400% increase in volume at 20 cm H<sub>2</sub>O. Figure 1b shows a CT example with a 52.9% increase in airway area, with the RMB increasing in diameter by 3 mm. CPAP was objectively shown to be an effective, relatively inexpensive, treatment for EDAC via bronchoscopy or CT imaging and it is hypothesised such independent measures enhance existing assessments of improvement.
Association of angiotensin II blockers with survival among men with prostate cancer: Results from CaPSURE.
Authors: A. Bardia, J. E. Cowan, P. Carroll, A. V. D'Amico, M. A. Carducci
Journal: Journal of Clinical Oncology (2011)

4538 Background: Pre-clinical data suggests that angiotensin II blockade can modulate androgen receptor expression in prostate cell lines leading to inhibition of cell growth, but clinical data to validate this finding is lacking. With angiotensin II blockers (ABs) commonly used in cardiology to manage blood pressure & congestive heart failure, we utilized a longitudinal database to evaluate the association between ABs & outcomes among men with prostate cancer. Methods: The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database includes data on men who had undergone radical prostatectomy &/or radiation treatment, &/or androgen deprivation therapy for prostate cancer at 40 community practices & academic centers throughout the US since 1995. Use of cardiac medications including ABs (both angiotensin converting enzyme blockers & angiotensin receptor blockers), were ascertained based on patient reported data. The association of ABs with the risk of prostate cancer specific mortality (PCSM) & all cause mortality (ACM) was evaluated using competing risks & Cox multivariable regression models adjusting for known prognostic variables & possible confounders (including concurrent aspirin &/or statins use). Adjusted Hazard Ratios (AHRs) with 95% Confidence Intervals (CIs) & p values are reported. Results: The study cohort comprised 6,017 men with a median post-treatment follow up of 64 months. At diagnosis, the mean age was 65.6 years & median PSA was 6.4 ng/ml. 38% patients had low, 36% intermediate, & 26% high D'Amico clinical risk group. Men who were taking ABs had significantly lower risk of PCSM (AHR: 0.47, CI: 0.34-0.65, p <0.01), & ACM (AHR: 0.68, CI: 0.60-0.77, p<0.01), than those not taking ABs. The lower risk was observed for both low & intermediate/high risk disease. With concomitant use of ABs with aspirin and statins, the reduction in risk was slightly higher for both PCSM (AHR: 0.32, CI: 0.22-0.47, p <0.01) & ACM (AHR: 0.51, CI: 0.44-0.60, p<0.01). Conclusions: The study findings suggest that men taking angiotensin II blockers might have significantly lower risk of prostate cancer & all cause mortality. These novel findings should be explored further in additional studies.
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
Authors: S.M. Swain, A. Schneeweiss, L. Gianni, J.J. Gao, A. Stein, M. Waldron-Lynch, S. Heeson, M.S. Beattie, B. Yoo, J. Cortes, J. Baselga
Journal: Annals of Oncology (2017)
P3.02b-051 Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study
Authors: Simon Baldacci, Julien Mazieres, Pascale Tomasini, Nicolas Girard, Florian Guisier, Clarisse Audigier Valette, Isabelle Monnet, Marie Wislez, Maurice Pérol, Pascal Dô, Eric Dansin, Charlotte Leduc, Etienne Giroux Leprieur, Denis Moro-Sibilot, Zoulika Kherrouche, Julien Labreuche, Alexis Cortot
Journal: Journal of Thoracic Oncology (2017)
P3.02b-083 Potential Usage of Afanitib in the Treatment of Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations
Authors: Taishi Harada, Yukiko Yamaba, Hiroki Hayata, Takashi Okuda, Yoshishige Kimura, Toshiyuki Komaki, Keizo Kagawa
Journal: Journal of Thoracic Oncology (2017)
Updated Recommendations for Cost-effectiveness Studies
Authors: Anna M. Maw, Nicole T. Shen, Dana R. Fletcher
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.
Authors: Thomas S. Lin, Beth Fischer, Kristie A. Blum, Pierluigi Porcu, Eric H. Kraut, Robert A. Baiocchi, Mollie E. Moran, Sarah Mitchell, Michael R. Grever, John C. Byrd
Journal: Blood (2008)
Clonal Selection in the Ontogeny and Evolution of Splenic Marginal Zone Lymphoma Confirming the Existence of Distinct Molecular Subtypes
Authors: Vasilis Bikos, Evangelia Stalika, Maria Karypidou, Panagiotis Baliakas, Zadie Davis, Patricia Algara, George Kanellis, Antonis Dagklis, Alexandra Traverse-Glehen, Sarah Hockley, Manuela Mollejo, Athanasios Tsaftaris, Achilles Anagnostopoulos, Maurilio Ponzoni, Francoise Berger, Pascale Felman, David Gonzalez, Estella Matutes, Miguel Angel Piris, Theodora Papadaki, Paolo Ghia, David Oscier, Chrysoula Belessi, Nikos Darzentas, Kostas Stamatopoulos
Journal: Blood (2012)
Novel Evidence That Very Small Embryonic Like Stem Cells (VSELs) Are Mobilized Into Peripheral Blood in Patients with Inflammatory Bowel Diseases – Correlation with Young Age and Severity of Disease.
Authors: Wojciech Marlicz, Edyta Paczkowska, Maciek Halasa, Boguslaw Machaliñski, Teresa Starzynska, Mariusz Z Ratajczak
Journal: Blood (2009)
90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients
Authors: Anton Hagenbeek, John Radford, Achiel Van Hoof, Umberto Vitolo, Ama Z.S. Rohatiner, Gilles Salles, Pierre Soubeyran, Herve Tilly, Angelika Bischof Delaloye, Wim L.J. van Putten, Franck Morschhauser
Journal: Blood (2010)
P3.02c-056 Interim Results From the Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Non-Small Cell Lung Cancer (NSCLC)
Authors: Jonathan W. Goldman, Ben George, Martin Gutierrez, Amy Ko, Peter O'Dwyer, Gregory Otterson, Hatem Soliman, Nataliya Trunova, David Waterhouse, Karen Kelly
Journal: Journal of Thoracic Oncology (2017)
PUB108 Concurrent Nab-Paclitaxel/Carboplatin Combined with Thoracic Radiotherapy in Locally Advanced Squamous Cell Lung Cancer (NCT01494415)
Authors: Kan Wu, Bing Xia, Xueqin Chen, Xiao Xu, Bing Wang, Peng Chen, Wenxin Li, Minna Zhang, Shenglin Ma
Journal: Journal of Thoracic Oncology (2017)
P1.05-019 Two Inflammatory Biomarkers MDC/CCL22 and BLC/CXCL13 Are Independently Associated with the Significant Risk of Early Stage Lung Adenocarcinoma
Authors: Yanwei Zhang, Keke Yu, Song Hu, Yuqing Lou, Chunxing Liu, Jianlin Xu, Rong Li, Xueyan Zhang, Huimin Wang, Baohui Han
Journal: Journal of Thoracic Oncology (2017)
P3.03-052 Diagnostic Utility of Mesothelin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma
Authors: Salih Emri, Gunnur Dikmen, Sevinc Sarinc Ulasli, Dorina Esendagli, Ugur Yılmaz, Nihal Ozek, Feride Severcan, Hamza Okur, Filiz Akbiyik
Journal: Journal of Thoracic Oncology (2017)
<scp>S</scp>ignificance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission
Authors: Naveen Pemmaraju, Hagop Kantarjian, Jeffrey L. Jorgensen, Elias Jabbour, Nitin Jain, Deborah Thomas, Susan O'Brien, Xuemei Wang, Xuelin Huang, Sa A. Wang, Marina Konopleva, Sergej Konoplev, Tapan Kadia, Rebecca Garris, Sherry Pierce, Guillermo Garcia‐Manero, Jorge Cortes, Farhad Ravandi
Journal: American Journal of Hematology (2017)

We sought to determine the significance of minimal residual disease (MRD) relapse in patients with ALL after achieving MRD negative status following induction and consolidation therapy. Between January 2003 and September 2014, 647 newly diagnosed patients were treated [HyperCVAD-based (n = 531); Augmented BFM (n = 116)]. Six hundred and one (93%) achieved complete remission (CR), and 546 (91%) became MRD negative. Fifty-five patients [HyperCVAD-based (n = 49); Augmented BFM (n = 6)] developed recurrence of MRD while still in morphological CR and are the subjects of this study. MRD was assessed by 6-color (4-color prior to 2009) multi-parameter flow cytometry (MFC) at CR and multiple time points thereafter. Their median age was 44 years (range, 18-72 years), median WBC at initial presentation was 7.3 K/µL-1 (range, 0.6-303.8 K/µL-1 ) and median bone marrow blast percentage 88% (range, 26-98%). The median time to MRD relapse was 14 months (range 3-58 months). Forty-four (80%) patients subsequently developed morphological relapse after median of 3 months (range, <1-33 months) from detection of MRD recurrence. Treatments received after MRD positivity and prior to morphological relapse: 16 continued maintenance chemotherapy; 15 received late intensification; 9 allogeneic stem cell transplant, 9 changed chemotherapy, 6 no further therapy. Only six remain alive and in CR1 and nine are alive after morphological relapse. MRD relapse detected by MFC at any time after achieving CR is associated with a high risk for morphological relapse. SCT can result in long-term remission in some patients. Prospective studies of long-term MRD assessments, together with less toxic treatment strategies to eradicate MRD, are warranted.
P29 Exercise intolerance in chronic thromboembolic disease: evaluation, underlying mechanisms and clinical implications
Authors: EM Swietlik, D Taboada, A Ruggiero, E Bales, L Harlow, A Fletcher, JE Cannon, K Sheares, DP Jenkins, J Pepke-Zaba, T Toshner
Journal: Thorax (2016)

<h3>Introduction</h3> Patients with chronic thromboembolic disease (CTED) without pulmonary hypertension commonly present with dyspnoea and fatigue. These symptoms limit physical function and impair quality of life. As resting haemodynamics in these patients are normal or near normal, stress testing may be a useful investigation to clarify mechanisms of functional impairment. <h3>Methods</h3> We prospectively evaluated baseline characteristics of patients with CTED in a single referral centre between January 2015 and June 2016. Newly referred patients with suspected CTED underwent a standard assessment as delineated in international guidelines<sup>1 </sup>with a minimum of 2 imaging modalities, resting and exercise right heart catheterisation (RHC) and additionally incremental cardiopulmonary exercise testing (CPET). All patients were assessed in a pulmonary endarterectomy MDT. <h3>Results</h3> Of 21 patients with confirmed CTED, 16 have completed the full assessment protocol (median age 53, 47–62). 14 (87%) were in functional class II/III. All patients had normal right ventricular function on echocardiography. Airway obstruction was present in 7 patients (44.5%). In majority of patients peak VO<sub>2</sub> and oxygen pulse were decreased and VE/VCO<sub>2</sub> at anaerobic threshold (AT) was increased (Table 1). CPET revealed 3 types of exercise limitation: combined cardiovascular and ventilatory limitation (n = 12), ventilatory limitation (n = 2) and limitation due to other reasons (n = 2). Peak oxygen consumption correlated with the symptoms domain of CAMPHOR (pulmonary hypertension specific quality of life measure) (p = 0.0242, R 0.56), cardiac output increase on exercise (p = 0.03, R 0.569) and VE/VCO<sub>2</sub> at anaerobic threshold (p = 0.012, R 0.608). Resting mPAP and PVR did not correlate with peak VO<sub>2 </sub>or symptoms. <h3>Conclusions</h3> We confirm the limited utility of resting measurements, including RHC in CTED for understanding exercise and functional limitation. CPET identified alternative causes for breathlessness and clarifies that patients with CTED are limited on exertion because of inability to increase cardiac output and hyperventilation. <h3>Reference</h3> Galie N, <i>et al</i>. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>EHJ</i> 2015;<b>58</b>(1):e129–e152.
P3.02b-043 Inter-Laboratory Comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma
Authors: Cleo Keppens, Sid Scudder, Partha Das, John Palma, Wei Wen, Nicola Normanno, Han Van Krieken, Elisabeth Dequeker
Journal: Journal of Thoracic Oncology (2017)
Hepatic arterial infusion (HAI) of oxaliplatin with either LV5FU2 or FOLFIRI in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Authors: A. Rahal, D. Malka, D. Goéré, V. Boige, T. De Baere, D. Elias, F. Deschamps, C. Rahal, M. Ducreux
Journal: Journal of Clinical Oncology (2011)

e14131 Background: Only limited options are available for pts with mCRC who failed systemic chemotherapy. This study evaluates the combination of HAI oxaliplatin with systemic chemotherapy in pts with refractory mCRC. Methods: Pts with colorectal liver metastases, measurable disease, ECOG performance status ≤ 1, and adequate bone marrow, liver and renal function were eligible. All patients had failed prior oxaliplatin-based, palliative, systemic chemotherapy. Pts received HAI oxaliplatin (85-100 mg/m2 over 2-hr infusion) with either Intravenous (iv) LV5FU2 (n=32) or FOLFIRI (n=9), every 2 weeks. Bevacizumab (n=14) or cetuximab (n=10) was added in 24 pts. Treatment was administered until unacceptable toxicity, disease progression or secondary surgical resection/radiofrequency ablation (RFA). Primary judgment criterion was objective response rate (ORR); secondary criteria included progression-free survival (PFS), overall survival (OS), secondary resection rate, and toxicity. Results: A total of 41 pts were included, M/F: 24/ 17; median age: 51 yrs (38-79), of whom 10 pts (25%) had extrahepatic disease. All have received previously oxaliplatin and 53% had irinotecan. Median number of treatment cycles was 8 (4-16). The most common grade 3/4 adverse events were neurotoxicity (15%), febrile neutropenia (15%), thrombocytopenia (10%), and skin rash (10%). ORR was 39% (including 1 CR), and disease stabilization was obtained in 46% (disease control rate, 85%). Curative-intent resection/RFA was performed in 16 pts (39%; including percutaneous RFA in 2 pts), of whom 5 achieved complete pathological response. Conclusions: HAI oxaliplatin with systemic chemotherapy (LV5FU2 or FOLFIRI, +/- bevacizumab /cetuximab) is effective and well tolerated in pts with mCRC after failure of systemic-only chemotherapy.
Temporal Trends in Quality of Care Among Recipients of Implantable Cardioverter-Defibrillators
Authors: John A. Dodson, Rachel Lampert, Yongfei Wang, Stephen C. Hammill, Paul Varosy, Jeptha P. Curtis
Journal: Circulation (2013)

The ICD Registry was established in 2006 in part to measure quality of care in patients undergoing implantation of implantable cardioverter-defibrillators (ICDs); however, whether outcomes have improved since initiation of the registry is unknown. Our objective was to examine changes over time in 3 quality metrics available from the registry.
P49 Does valsalva manoeuvre reduce the risk of complications in CT-guided lung biopsies?
Authors: AE Syed, I Syed, R Ahmed, O Parvu, L Pancione, A Alvi, K Novacic, R Akram
Journal: Thorax (2016)

<h3>Introduction</h3> Multiple complications in CT-guided lung biopsy have been described with pneumothorax known to be the commonest.<sup>1</sup> This often leads to patients being admitted to hospital for observation or even drainage. We hypothesised that increased intrathoracic pressure may reduce complications and a comparative retrospective cohort study was performed with the types and rates of complications recorded in patients instructed to perform a Valsalva manoeuvre versus those who were not. <h3>Methods</h3> Patients who underwent CT-guided lung or pleural biopsies performed by multiple operators between January 2005 and December 2014 at Queens Hospital, Essex, UK, were retrospectively identified. Information from RIS reports and images from PACS were analysed. Patients were stratified into two groups, those who undertook Valsalva at time of biopsy and those who did not. Complication rates were assessed for haemoptysis, haemothorax and pneumothoraces including those requiring chest drain insertion. Statistical analysis was performed using Chi square test. <h3>Results</h3> 791 procedures were performed over 10 years, 420 patients undertook Valsalva manoeuvre with mean ages 70.1 years ±SD 12.54: range 21–93. The other 371 patients did not undertake a Valsalva manoeuvre. Their mean ages were 71.1 years ±SD 11.52: range 27–91. In total, 119 patients had complications post-procedure: 64 in the non-Valsalva group vs 55 in the Valsalva group (17.25% vs 13.10%, p = 0.05). Rates of haemoptysis were significantly reduced with Valsalva (2.16% vs 0.24%, p = 0.006). Pneumothorax requiring chest drain (2.70% vs 1.43%, p = 0.10) and those managed conservatively (12.40% vs 11.19%, p = 0.30) were higher in the non-Valsalva group. Rate of haemothorax (0.24% vs 0%, p = 1) was greater in the Valsalva group. <h3>Conclusion</h3> Our study shows that Valsalva manoeuvre at the time of biopsy helps reduce the rate of complications, with a statistically significant decrease in rate of haemoptysis. Rates of pneumothoraces requiring chest drain insertion and other pneumothoraces were also reduced. The differences could be explained by physiological changes in pulmonary wedge pressure and positive end expiratory pressure brought about by increased intrathoracic pressure following Valsalva manoeuvre. <h3>Reference</h3> Manhire A, Charig M, Clelland C, <i>et al</i>. Guidelines for radiologically guided lung biopsy. British thoracic society guidelines. <i>Thorax</i> 2003;<b>58</b>:920–936.
Soluble CD30 (sCD30), a Marker of Th2 Polarization, Is Elevated in Patients with Autoimmune Hemolytic Anemia (AIHA) but Not with Idiopathic Thrombocytopenia (ITP).
Authors: Eugene R. Ahn, Eckhard Podack, Wenche Jy, Carlos J. Bidot, Lawrence Horstman, Yeon S. Ahn
Journal: Blood (2005)
S60 Lung cancer surgical survival and volume in england
Authors: D West, P Beckett, A Khakwani, R Hubbard, R Dickinson, I Woolhouse
Journal: Thorax (2016)

<h3>Introduction</h3> The National Lung Cancer Audit has collected data for over 10 years demonstrating gradually rising resection rates in the UK. The Clinical (formerly Consultant) Outcomes Programme (COP) is an NHS England initiative, managed by HQIP, using national audit data to publish quality measures at the level of individual consultants. The lung cancer COP focusses on activity at individual surgeon level, and on survival at unit level. The first lung cancer COP in 2014 demonstrated overall 30 and 90-day survival of 97.8% and 95.5%. <h3>Methods</h3> Data submitted to the NLCA for patients having curative-intent surgery who underwent surgery in 2013 was sent to the clinical lead at each surgical unit for validation and addition of responsible surgeon GMC number, with the option to add surgical cases if they were not included in the supplied dataset. Date of death was derived by a link to the Office of National Statistics. Units reporting unadjusted survival proportions more than three standard errors outside the national mean (“alarm” level) at 30 or 90 days were identified as statistical outliers. <h3>Results</h3> All of the 28 surgical units in England participated in the audit, submitting a total of 4892 cases. Median annual unit activity was 156 resections (IQR 99–221, range 39–481). Median annual activity for individual surgeons was 39 (IQR 20–52, range 1–152). Overall 30-day survival was 98% and 90-day survival was 96%. There were no units with statistical outliers at the alarm level at 30-days and 90-days (see Figure). <h3>Conclusion</h3> Volume of activity varies widely by unit and individual surgeon. Survival after lung cancer surgery is very high, is improving, and is not statistically significantly different across the surgical units in England. This suggests that lung cancer teams may still be risk averse when considering surgical treatment of their patients. Reasons why patients die between 30 and 90 days is worthy of further investigation. Case-mix adjustment will be needed to allow robust comparisons between units.
P2.02-058 Moderately Hypofractionated Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Single Institution Retrospective Analysis
Authors: Alessio Bruni, Elisa D'Angelo, Gabriele Guidi, Bruno Meduri, Stefano Scicolone, Polina Vassylieva, Nicola Maffei, Filippo Bertoni, Tiziana Costi, Frank Lohr
Journal: Journal of Thoracic Oncology (2017)
Lille Scoring System Rather Than DIPSS Is a Better Predictive of Overall Mortality After Allogeneic Hematopoietic Cell Transplantation (HCT) for Primary Myelofibrosis Using Reduced Intensity Conditioning: A Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)
Authors: Vikas Gupta, Kwang W Ahn, Xiaochun Zhu, Zhenhuan Hu, Parameswaran Hari, Richard T. Maziarz, Jorge E. Cortes, Matt Kalaycio, Wael Saber
Journal: Blood (2012)